References
- Cain LE, Logan R, Robins JM, et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med. 2011;154:509–515.
- Patrick GC, Wei CY, Christiane HM, et al. A meta‑analysis comparing 48‑week treatment outcomes of single and multi‑tablet antiretroviral regimens for the treatment of people living with HIV. AIDS Res Ther. 2018;15:17.
- Panel on Antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of healtg and human services. [cited 2019 Feb 27]. Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
- EACS guidelines version 9.1 [Internet], October 2018. Available from: http://www.eacsociety.org.
- Olalla J, Pérez-Stachowski J, Tortajada B, et al. Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks. BMC Pharmacol Toxicol. 2018;19:63.
- Krentz HB, Campbell S, Lahl M, et al. De-simplifying single-tablet antiretroviral treatments: uptake, risks and cost savings. HIV Med. 2019;20:214–221.
- Sharon L, Antela A, Clumeck N, et al. Dolutegravir plus Abacavir-Lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807–1818.
- AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology and the National AIDS Plan. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). Enferm Infecc Microbiol Clin. 2019;37:195–202.